Literature DB >> 28463524

JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism.

Eric J Keller1, Laura Kulik2, Zoran Stankovic3, Robert J Lewandowski4, Riad Salem4, James C Carr1,4, Susanne Schnell1,5, Michael Markl1,5, Jeremy D Collins1,4.   

Abstract

OBJECTIVE: The objective of this study is to evaluate the ability of spleen volume, blood flow, and an index incorporating multiple measures to predict cirrhosis-associated hypersplenism.
MATERIALS AND METHODS: A total of 39 patients (14 women and 25 men; mean [± SD] age, 52 ± 10 years) with cirrhosis and sequelae of portal hypertension underwent 4D flow MRI and anatomic 3-T MRI performed before and after contrast administration. Unenhanced 4D flow MRI was used to assess abdominal hemodynamics, and splenic volumes were measured on T1-weighted gradient-recalled echo MRI. Relationships among demographic characteristics, blood component counts, splenic volume, arterial flow, venous flow, and the percentage of shunted portal flow were assessed in 29 consecutive patients (i.e., the derivation group), to develop a splenic flow index. This index was assessed along with splenic volume and blood flow alone in 10 additional consecutive patients (i.e., the validation group) via ROC curve analysis, to identify platelet counts of less than 50 × 103 cells/μL, leukocyte counts of less than 3.0 × 103 cells/μL, or both.
RESULTS: In the derivation cohort (platelet count, 129 ± 76 × 103 cells/μL), splenic volume, arterial flow, venous flow, and the percentage of shunted portal flow were inversely correlated with platelet counts (ρ = -0.68, -0.68, -0.56, and -0.36, respectively; p < 0.05). Adding splenic volume to arterial flow and the product of venous flow and the percentage of shunted portal flow indexed to the body surface area yielded superior correlations with platelet counts, leukocyte counts, and the degree of severity of hypersplenism (ρ = -0.75, -0.48, and -0.75, respectively; p ≤ 0.001) and predicted severe hypersplenism (sensitivity, 100%; specificity, 100%) in the validation cohort (platelet count, 93 ± 71 × 103 cells/μL).
CONCLUSION: A splenic flow index that incorporates both splenic volume and blood flow is a better indicator of hypersplenism than is splenic volume alone.

Entities:  

Keywords:  4D flow MRI; abdominal hemodynamics; cirrhosis; hypersplenism; thrombocytopenia

Mesh:

Year:  2017        PMID: 28463524     DOI: 10.2214/AJR.16.17620

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Hemodynamic measurements with an abdominal 4D flow MRI sequence with spiral sampling and compressed sensing in patients with chronic liver disease.

Authors:  Octavia Bane; Steven Peti; Mathilde Wagner; Stefanie Hectors; Hadrien Dyvorne; Michael Markl; Bachir Taouli
Journal:  J Magn Reson Imaging       Date:  2018-10-14       Impact factor: 4.813

Review 2.  Abdominal applications of quantitative 4D flow MRI.

Authors:  Thekla H Oechtering; Grant S Roberts; Nikolaos Panagiotopoulos; Oliver Wieben; Alejandro Roldán-Alzate; Scott B Reeder
Journal:  Abdom Radiol (NY)       Date:  2021-11-27

Review 3.  Four-Dimensional Flow MRI of Abdominal Veins: A Systematic Review.

Authors:  Simon O Haarbye; Michael B Nielsen; Adam E Hansen; Carsten A Lauridsen
Journal:  Diagnostics (Basel)       Date:  2021-04-24

4.  Quantification of the Hemodynamic Changes of Cirrhosis with Free-Breathing Self-Navigated MRI.

Authors:  Ryan L Brunsing; Dustin Brown; Hashem Almahoud; Yuko Kono; Rohit Loomba; Irene Vodkin; Claude B Sirlin; Marcus T Alley; Shreyas S Vasanawala; Albert Hsiao
Journal:  J Magn Reson Imaging       Date:  2021-02-16       Impact factor: 5.119

5.  Liver stiffness assessed by real-time two-dimensional shear wave elastography predicts hypersplenism in patients with Wilson's disease: a prospective study.

Authors:  Jiajia Wang; Minxia Hu; Qiang Zhu; Lanting Sun
Journal:  BMC Med Imaging       Date:  2022-02-11       Impact factor: 1.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.